Wholesale of pharmaceutical and medical goods
GILEAD SCIENCES NORWAY AS
Revenue 2024
NOK 186.2m
Operating profit
NOK 6.5m
Equity
NOK 85.6m
Incorporated
2007
Employees
5
Share capital
NOK 100,000
Key figures · 2024
Current ratio
2.98
Equity ratio
67.2%
Key figures over time · 2024
| Key figures | 2024 | Trend |
|---|---|---|
| Lønnsomhet | ||
| Operating margin (%%) | 3.5% | |
| Net margin (%%) | 3.1% | |
| Return on assets (%%) | 5.1% | |
| Likviditet | ||
| Current ratio | 2.98 | |
| Working capital | 82.9m | |
| Soliditet | ||
| Equity ratio (%%) | 67.2% | |
| Debt-to-equity ratio | 0.49 | |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.